112 results
Page 4 of 6
8-K
0ctwijthynys5zs qz
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-2.1
ebyiez 4e9svax8o3df
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-99.1
z37kvm5jedt5upscfo
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-99.3
13mvzm 8a
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-99.1
h8f3jtxwhgn00p 4zw7r
26 Oct 20
Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral
6:10am
8-K
t9t36b
26 Oct 20
Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral
6:10am
8-K
EX-99.1
pg4eiir0tg
13 Feb 20
Syros Announces $60 Million Loan Facility with Oxford Finance LLC
8:51am
8-K
EX-99.1
lkcmv z9vnbpawte3q
13 Jan 20
Regulation FD Disclosure
6:11am
8-K
EX-99.2
xqtd3p ug
13 Jan 20
Regulation FD Disclosure
6:11am
8-K
EX-99.1
idis 6bjj099
2 Dec 19
Regulation FD Disclosure
7:03am
8-K
7v06c
24 Oct 19
62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence
8:36am
8-K
EX-99.1
ohi8n708
24 Oct 19
62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence
8:36am